Significantly less heroin cravings were reported in the extended-release naltrexone group and treatment satisfaction was also reported higher in this group compared to the buprenorphine-naloxone group.
New pharmacotherapies in combination with psychotherapy and counseling have proven effective in preventing relapse.
The FDA has permitted marketing of the first mobile app to help treat substance abuse use disorders, including alcohol, cocaine, marijuana, or other stimulants.
A 39-year-old man presents to the emergency department with 3 days of progressive bilateral leg pain, nausea, malaise, and no other symptoms. What additional tests should you order to make a correct diagnosis?
A 12-week CBT program led to reductions in PTSD and substance abuse in transgender women with HIV.
CPA reports on a new analgesic formulation designed to provide both immediate and prolonged analgesia for up to 12 hours in patients with acute pain.
Clinical Pain Advisor Articles
- Fibromyalgia Screening in Patients With Chronic Pain: Two Simple Tests
- Pain In Elite Athletes: IOC Recommendations on Contributing Factors and Treatment Approach
- Chronic Pain Associated With Traumatic Brain Injury: Causes and Management
- Migraine Frequency Correlated With Depression and Anxiety
- New Daily Persistent Headache Associated With Sleep Disturbances in Children
- Neuroimaging for Chronic Pain: IASP Consensus Statement
- Cannabis Use Associated With Aberrant Drug Behaviors
- Independent Pharmacies Expanding Services Available to Patients
- Ketamine Exhibits Effective Pain Relief for Refractory Headaches
- Vibrating Gloves Significantly Reduce Osteoarthritis-Related Hand Pain
- Brain Plasticity in Patients With Complex Regional Pain Syndrome
- Virtual Reality Reduces Pain in Children During Routine Blood Draw
- FDA Expresses Safety Concern Over Kratom
- Opioid Manufacturers Providing Training for Clinicians
- Fluoroscopically Guided Sacroiliac Interventions: Appropriate Use Criteria